Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Arcus Biosciences (RCUS) Stock Price & Analysis
397 Followers
RCUS Stock Chart & Stats
Day’s Range$14.65 - $15.19
52-Week Range― - ―
Previous Close$14.84
Volume44.70K
Average Volume (3M)N/A
Market Cap
$1.35B
Enterprise Value$589.43M
Total Cash (Recent Filing)$759.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 07, 2024EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.04
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda-1.93
Forecast
1Y Price Target
$42.14Price Target Upside183.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Arcus Biosciences News
PremiumCompany Announcements
Arcus Biosciences Announces Anti-TIGIT Program Update
PremiumCompany Announcements
Arcus Biosciences Announces Board Reshuffle and New Appointment
PremiumCompany Announcements
Arcus Biosciences Sells Equity to Gilead Under Section 4(a)(2)
PremiumCompany Announcements
Arcus Biosciences Enhances Partnership with Gilead Sciences
Bulls Say, Bears Say
Bulls Say
Clinical Trial DataArcus will be presenting mature PFS and updated ORR data from its P2 Edge-Gastric trial at ASCO, showing promise in treatment for upper GI cancers.
Financial HealthArcus has a strong cash position with $1.2 billion in cash and equivalents, expected to fund operations into 2027.
Strategic CollaborationsGILD's increased investment and focus on STAR-121 could very well lead the companies down the path of acquisition.
Bears Say
Clinical Trial SetbacksTIGIT sentiment is cooling following the latest setbacks and increased potential for a miss in clinical trials.
Drug EfficacyCasdatifan's potential in clear cell renal cell carcinoma is still largely theoretical, with efficacy yet to be proven.
Financial PerformancePrice Target lowered to $42 to account for increased dilution and loss of ARC-10, reflecting a more conservative valuation.
---
Ownership Overview
41.05% Insiders
17.17% Mutual Funds
17.66% Other Institutional Investors
24.12% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Currently, no data Available
What is Arcus Biosciences Inc’s market cap?
Currently, no data Available
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is May 07, 2024 which is in 14 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Feb 21, 2024. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$1.025 by -$0.055.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -$1.
How many shares outstanding does Arcus Biosciences Inc have?
Currently, no data Available
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$1.08 in its last earnings report, missing expectations of -$1.025. Following the earnings report the stock price went up 19.866%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Among the largest hedge funds holding Arcus Biosciences Inc’s share is Invus Financial Advisors, LLC. It holds Arcus Biosciences Inc’s shares valued at 31M.
---
Arcus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.14 (183.96% Upside)
$42.14 (183.96% Upside)
Hedge Fund Trend
Decreased
By 99.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $319.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.72%
12-Months-Change
Fundamentals
Return on Equity
-54.87%
Trailing 12-Months
Asset Growth
-18.59%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
---
RCUS Earnings Call
Q4 2024
0:00 / 0:00
---
RCUS Stock 12 Months Forecast
Average Price Target
$42.14
▲(183.96% Upside)
Technical Analysis
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+2.65%
assigned a buy rating 2 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +2.65% per trade.
---